X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-zealand-pharmas-drug-low-blood-sugar-children-2023-12-23/
https://www.globenewswire.com/news-release/2023/08/30/2734023/0/en/Zealand-Pharma-announces-designation-of-priority-review-by-the-US-FDA-for-dasiglucagon-in-congenital-hyperinsulinism.html
https://www.globenewswire.com/news-release/2023/06/30/2698007/0/en/Zealand-Pharma-submits-New-Drug-Application-to-US-FDA-for-dasiglucagon-in-congenital-hyperinsulinism.html
https://www.globenewswire.com/news-release/2023/06/26/2694124/0/en/Zealand-Pharma-Submits-Marketing-Authorization-Application-for-Dasiglucagon-for-Treatment-of-Severe-Hypoglycemia-in-Diabetes-to-the-European-Medicines-Agency.html
https://www.globenewswire.com/news-release/2022/09/19/2517958/0/en/Zealand-Pharma-Presents-Data-from-Phase-3-Trial-of-Dasiglucagon-in-Congenital-Hyperinsulinism-at-the-60th-Annual-ESPE-Meeting.html
https://www.globenewswire.com/news-release/2022/09/19/2517958/0/en/Zealand-Pharma-Presents-Data-from-Phase-3-Trial-of-Dasiglucagon-in-Congenital-Hyperinsulinism-at-the-60th-Annual-ESPE-Meeting.html
https://www.globenewswire.com/news-release/2022/09/07/2511078/0/en/Zealand-Pharma-Announces-Global-License-and-Development-Agreement-with-Novo-Nordisk-for-ZEGALOGUE-dasiglucagon.html
https://www.globenewswire.com/news-release/2022/09/07/2511078/0/en/Zealand-Pharma-Announces-Global-License-and-Development-Agreement-with-Novo-Nordisk-for-ZEGALOGUE-dasiglucagon.html
https://medwatch.com/News/Pharma___Biotech/article14043778.ece?utm_campaign=MedWatch%20Newsletter&utm_content=2022-05-19&utm_medium=email&utm_source=medwatch_com
https://www.globenewswire.com/news-release/2022/03/11/2401950/0/en/Correction-Zealand-Pharma-Significant-Advancement-of-Clinical-Pipeline-and-Building-Commercial-Momentum-Key-Data-for-Glepaglutide-and-Dasiglucagon-Programs-Expected-in-2022.html
https://www.pharmacompass.com/pdf/news/zealand-pharma-completes-patient-enrollment-in-phase-3-trial-of-dasiglucagon-in-children-with-congenital-hyperinsulinism-1645177744.pdf
https://www.pharmacompass.com/pdf/news/zealand-pharma-and-deka-research-development-corp-announce-collaboration-agreement-to-advance-development-of-infusion-pump-to-be-used-with-dasiglucagon-for-treatment-of-congenital-hyperinsulinism-chi-1638767953.pdf
https://www.globenewswire.com/news-release/2021/06/24/2252441/0/en/Zealand-Pharma-Announces-U-S-Commercial-Availability-of-ZEGALOGUE-dasiglucagon-injection.html
https://www.globenewswire.com/news-release/2020/12/15/2145350/0/en/Zealand-Pharma-announces-data-from-the-first-phase-3-trial-with-dasiglucagon-in-Congenital-Hyperinsulinism-CHI.html
https://www.globenewswire.com/news-release/2020/06/14/2047740/0/en/Zealand-Pharma-presents-clinical-and-non-clinical-evidence-for-dasiglucagon-rescue-therapy-at-the-80th-Scientific-Sessions-of-the-American-Diabetes-Association.html
https://www.biospace.com/article/zealand-sets-the-stage-for-dasiglucagon-nda-following-fourth-straight-phase-iii-win-in-severe-hypoglycemia/?s=95
https://endpts.com/hypoglycemia-epipen-clears-phase-iii-hurtles-toward-fda-decision/
https://www.nasdaq.com/press-release/zealand-pharma-reports-completion-of-the-second-and-pivotal-phase-3-trial-with-dasiglucagon-for-th-20180528-00102
Market Place
Share 
